Cargando…

TARBP2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a lethal human malignancy and a leading cause of cancer‐related death worldwide. Patients with HCC are often diagnosed at an advanced stage, and the prognosis is usually poor. The multikinase inhibitor sorafenib is the first‐line treatment for patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Hui‐Huang, Li, Chih‐Wei, Hong, Chih‐Chen, Sun, Hung‐Yu, Chiu, Ching‐Feng, Ou, Da‐Liang, Chen, Pai‐Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441883/ https://www.ncbi.nlm.nih.gov/pubmed/30657254 http://dx.doi.org/10.1002/1878-0261.12449

Ejemplares similares

TARBP2 promotes tumor angiogenesis and metastasis by destabilizing antiangiogenic factor mRNAs
por: Zhou, Meicen, et al.
Publicado: (2021)

TARBP2 Suppresses Ubiquitin-Proteasomal Degradation of HIF-1α in Breast Cancer
por: Li, Jie-Ning, et al.
Publicado: (2021)

TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer
por: Wang, Ming-Yang, et al.
Publicado: (2019)

Loss of TARBP2 Drives the Progression of Hepatocellular Carcinoma via miR-145-SERPINE1 Axis
por: Li, Li-Man, et al.
Publicado: (2021)

Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells
por: Chen, Chih-Ta, et al.
Publicado: (2020)

Corrigendum: Loss of TARBP2 Drives the Progression of Hepatocellular Carcinoma via miR-145-SERPINE1 Axis
por: Li, Li-Man, et al.
Publicado: (2021)

SUMOylation of TARBP2 regulates miRNA/siRNA efficiency
por: Chen, Cheng, et al.
Publicado: (2015)

CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling
por: Chen, Zibo, et al.
Publicado: (2022)

Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma
por: Caramuta, Stefano, et al.
Publicado: (2013)

Clinicopathological Significance of TARBP2, APP, and ZNF395 in Breast Cancer
por: Oi, Ryoko, et al.
Publicado: (2016)

Nanog Overcomes Reprogramming Barriers and Induces Pluripotency in Minimal Conditions
por: Theunissen, Thorold W., et al.
Publicado: (2011)

Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors
por: Chen, Yunching, et al.
Publicado: (2017)

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()
por: Su, Jung-Chen, et al.
Publicado: (2014)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
por: Tan, Wenliang, et al.
Publicado: (2018)

A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma
por: Lin, Chih-Lang, et al.
Publicado: (2023)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

TaRBP1 stabilizes TaGLTP and negatively regulates stripe rust resistance in wheat
por: Li, Yue, et al.
Publicado: (2023)

Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
por: Hsu, Chih-Hung, et al.
Publicado: (2014)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

The Pluripotency Factor Nanog Protects against Neuronal Amyloid β-Induced Toxicity and Oxidative Stress through Insulin Sensitivity Restoration
por: Chang, Ching-Chi, et al.
Publicado: (2020)

A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib
por: Pietrobono, Silvia, et al.
Publicado: (2021)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
por: Zheng, Ning, et al.
Publicado: (2019)

Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma
por: Liang, Kung-Hao, et al.
Publicado: (2021)

Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma
por: Shi, Hewen, et al.
Publicado: (2023)

Molecular crowding overcomes the destabilizing effects of mutations in a bacterial ribozyme
por: Lee, Hui-Ting, et al.
Publicado: (2015)

Expression of TARBP1 protein in human non-small-cell lung cancer and its prognostic significance
por: Ye, Jingmei, et al.
Publicado: (2018)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

LINC01526 Promotes Proliferation and Metastasis of Gastric Cancer by Interacting with TARBP2 to Induce GNG7 mRNA Decay
por: Zhou, Jin-Yong, et al.
Publicado: (2022)

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
por: Yang, Xiao-Dong, et al.
Publicado: (2021)

Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms
por: Chen, Jiang, et al.
Publicado: (2020)

A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007–2015
por: Huang, Chi-Chun, et al.
Publicado: (2019)

Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma
por: Lee, Wei‐Chen, et al.
Publicado: (2020)

Cyclohexylmethyl Flavonoids Suppress Propagation of Breast Cancer Stem Cells via Downregulation of NANOG
por: Liao, Wen-Ying, et al.
Publicado: (2013)

Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis
por: Hsu, Tung-Wei, et al.
Publicado: (2023)

Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
por: Huang, Kuo-Wei, et al.
Publicado: (2022)

Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan
por: Chan, Kun-Ming, et al.
Publicado: (2019)

An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells
por: Tang, Shuyao, et al.
Publicado: (2016)

CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death
por: Ding, Bisha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sschn9i0e390jgeqvhfedb5tdj